- Conditions
- Macular Degeneration
- Interventions
- Abicipar Pegol, Ranibizumab, Sham Procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 949 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 262
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Retinopathy
- Interventions
- Squalamine Lactate Ophthalmic Solution 0.2%
- Drug
- Lead sponsor
- Starr Muscle
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Retinal Vein Occlusion
- Interventions
- Not listed
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetic Macular Edema
- Interventions
- 2.0 mg intravitreal aflibercept, 1.25 mg intravitreal bevacizumab, 0.3 mg intravitreal ranibizumab
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 90
- States / cities
- Tucson, Arizona • Beverly Hills, California • Loma Linda, California + 72 more
- Conditions
- Macular Degeneration
- Interventions
- bevasiranib, ranibizumab
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 338 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fresno, California + 47 more
- Conditions
- Fibrovascular Pigment Epithelial Detachment
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Telangiectasia
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
- Conditions
- Retinal Vein Occlusion
- Interventions
- Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation
- Drug · Procedure
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Exudative Age-related Macular Degeneration
- Interventions
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection
- Drug
- Lead sponsor
- Lpath, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 44
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- Ranibizumab 0.5mg
- Drug
- Lead sponsor
- Southern California Desert Retina Consultants, MC
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 4
- States / cities
- Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
- Conditions
- Retinal Vein Occlusion
- Interventions
- ranibizumab, Peripheral Laser
- Drug · Other
- Lead sponsor
- Peter A Campochiaro, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Sacremento, California • Augusta, Georgia + 3 more
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
- Biological · Procedure
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 986 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 76
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone intravitreal implant (0.7 mg), Intravitreal anti-VEGF injection
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Bakersfield, California • Oxnard, California • Santa Barbara, California + 1 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Fovista®, bevacizumab, ranibizumab, aflibercept
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 21 more
- Conditions
- Diabetic Macular Edema
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab, Laser photocoagulation
- Drug · Procedure
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept
- Drug
- Lead sponsor
- Southeast Clinical Research Associates, LLC
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Statesville, North Carolina
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Squalamine Lactate Ophthalmic Solution, 0.2%, Placebo Ophthalmic Solution, ranibizumab
- Drug
- Lead sponsor
- Ohr Pharmaceutical Inc.
- Industry
- Eligibility
- 50 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Hagerstown, Maryland • New York, New York + 1 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Central Retinal Vein Occlusion
- Interventions
- Ranibizumab (Lucentis)
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Bakersfield, California • Santa Barbara, California • Santa Maria, California
- Conditions
- Retinal Vein Occlusion
- Interventions
- Ranibizumab (Lucentis )
- Drug
- Lead sponsor
- Vitreous -Retina- Macula Consultants of New York
- Other
- Eligibility
- Not listed
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Edema, Macular Degeneration
- Interventions
- Ranibizumab
- Other
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Age-related Macular Degeneration
- Interventions
- Fovista® (anti-PDGF BB) plus anti-VEGF
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more